• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Cretex Companies CEO Steps Down

    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread

    Endoscopic Hemostasis Devices Market Valued at $730 Million

    Henry Schein Buys Majority Interest in Prism Medical Products

    Boston Scientific's Vercise Genus DBS Earns FDA Approval
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Fixing Face Mask Form and Function

    The Heart of the Matter: Trends in Cardiology

    Virtually the Same? The Challenges of Online Conferences

    Digital Health Delivers During a Year for the Ages

    Advanced Technology for Staking and Swaging Medical Plastics
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Unicep

    PTI Engineered Plastics Inc.

    maxon

    Spectrum Plastics Group

    Concise Engineering
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Meeting Critical Ventilator Product Requirements Amid Pandemic

    Impact of COVID-19 on the Medtech Supply Chain

    Finding the Upside to a Challenging Year

    Preparing Your Design Controls for FDA Approval

    A 'Trial and Error' Approach to Micromolded Parts
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Concise Engineering

    PTI Engineered Plastics Inc.

    Creganna Medical, part of TE Connectivity

    Element

    MW Life Sciences
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    The Buck Starts Here

    ...

    The Buck Starts Here
    Related CONTENT
    • TPI Partners with Zeiss
    • Freudenberg Medical Expands Injection Molding Operations
    • CHF Solutions Appoints CEO
    • Medtech Matters: Surgeons Scrubbing In Virtually
    • FineHeart Successfully Tests Wireless TET System
    Steve Maylish, Chief Commercial Officer, Fusion Biotec, and Ben Bobo, CEO, NeuroTemp LLC06.06.17
    Commercialization is the confluence of all prior activities, a time of high investment and high anxiety. Here the rubber meets the road—yet for a new device, visibility on that road is often quite poor. A regulatory agency approved your device for sale, but how do you get traction? If you build it (to meet your pricing target), will they come?

    Although established medical device companies have a more predictable path, product commercialization brings risk and uncertainty. Go-to market strategies often resemble a slog in the fog rather than a well-executed plan. Companies pull familiar levers of market research, product design, and clinical trials. Marketing applies the leverage of key opinion leaders (KOLs), Centers of Excellence (COE), peer-reviewed journals, clinical partners, and voice of the customer to maximize the offering’s impact and drive commercial certainty up and down corporate structure. However, according to a survey of 2,240 executives from McKinsey Global, only 39 percent feel confident in their company’s ability to commercialize a medical device. Commercialization is truly an art form; no one product, market, or customer acts predictably to the traditional commercial levers.

    In reality, no one can predict whether a product will be successful and become standard of care. The unreasonable pressure executives endure to deliver a revenue- producing product under budget and under schedule adds to this dynamic. Most of the mistakes that cost investors millions, significantly dilute key shareholders, hurt stock prices, and run startups out of business are made here. Commercialization is the culmination of a dream to deliver a disruptive and breakthrough medical device, but innovators, inventors, and engineers can fail to adequately filter ideas and designs through the most important element—the customer. Teams can fall victim to “drinking their own Kool-Aid” or to the pressure of executing the plan and miss the basics of product development.

    Presuming market research identified a unique clinical problem to solve with large market potential and a disruptive design approach, the Customer Requirements Document (CRD) is the greatest determinant of a successful commercial launch. The CRD provides specifications of what the customer wants the product to do in a clinical environment, based on their understanding of the technology. The Product Requirements Document (PRD) provides all the engineering requirements for what the product should do.

    When the CRD and PRD are misaligned, the product may not achieve commercial liftoff. The initial CRD and PRD provide a line in the sand to start development. However, these are living documents that evolve during the development process—expect them to evolve as KOLs interact with the device and provide feedback. Too often, this feedback occurs late in the process. This should change because of the new U.S. Food and Drug Administration (FDA) usability requirements. (Some of these new requirements are outlined in my article entitled “The Human Factor” in the May issue of MPO.)

    These evolving product features and iterations will, however, be in direct conflict with budgets, timelines, and expectations of executives and investors. The process can be cut short as undue pressure is applied; the product has a higher chance of failing in the clinical setting in these cases. An experienced R&D leader should provide a buffer between the development and executive teams. Investors will espouse—and project leaders will confirm—that projects usually take twice as long and cost twice as much as initially expected. This reality is often based on tasks unknown during budgeting and the discovery process of development. Project plans show milestones and a waterfall process, but feedback and iteration underlie the entire process.

    No one is prepared when a product misses its clinical mark during clinical studies. The design can be prototyped and tested, but the team can still fail to appreciate the impact of environmental factors on their design, customer requirements, or the technology’s failure to deliver on its promise. Since iterating the design at the end of development is expensive and time consuming, many assume clinical problems will be solved with enough training and education.

    One company developed a novel non-invasive monitoring technology and spent six years and over $12 million on a design unsuitable for the ICU environment and an accuracy that would never be clinically acceptable. Had the company invested in early prototypes with leading neurosurgeons and nurses, their understanding of the customer requirements and target the design needed to hit would have been dramatically different. This is the innovator’s dilemma: not listening to the customer/user throughout the process.

    Throughout the product development process, “commercialization” activities happen in parallel. These can be as varied as human factors, design for manufacturing, or clinical testing. The main factor in determining the market for a new device is identifying an unmet clinical need for a procedure, or a step in a procedure. Some companies are formed by an idea looking for an application. It’s far better to start with an unmet clinical need.

    For example, one company pioneered beating heart surgery. The unmet clinical need in this case was preventing patients from undergoing open-heart surgery on a heart/lung machine and avoiding the deleterious effects of cardiopulmonary bypass. The result: the company took 20 percent of the coronary artery bypass market and was sold for $313 million.

    There is a huge difference between how a large established medical device (LEMD) company and a start-up launches a product. A LEMD has established sales channels (40- to 200-person sales forces), KOLs, and an established brand name for product quality. They also have established national accounts that can be leveraged to promote the product into leading centers. Even with these built-in advantages, LEMDs still take a conservative approach to product introductions to customers.

    Typically, they identify thought leader sales representatives (TLRs) in their organizations that influence the sales teams. They target COEs in territories of TLRs to initiate the product launch with the purpose of developing sales messaging and “recipes for success.” Twenty to twenty five centers may be targeted in this phase to flesh out the price, promotion, and positioning of the product in the customer’s mind. Usually four to six months afterward, they will do a market release with the full sales organization. The TLRs will be active in this phase to lend credibility and gravitas to the product launch.

    Startups have a different challenge. They lack a brand name, national accounts, a distribution channel of sales pros with KOLs, and sometimes funding. A startup has two distinct options to develop its sales channel. First is a direct sales force, which brings the advantage of controlling the sales strategy. Going direct is expensive and adds dramatically to the burn rate. This can materially impact the company’s operations if the product is not ready for launch. Most startups do not have the luxury to add an eight- to 10-person sales team. Experienced, successful sales reps are highly paid, but inexperience doesn’t get you through the door.

    Identifying and training independent distributor sales reps to sell and promote the product is another option. However, the decision to use distributor reps should not be made for purely financial reasons. If the distributor reps also promote products with shorter sales cycles and minimal levels of approval, the startup can lose control of their strategy. It’s easy to feel abandoned; distributors typically have multiple products in their bag.

    Startup medical device companies passionately usher in new technology while facing the challenges of funding, development, and regulatory agencies in order to change the market and bring life-saving technology to patients in need. It may have taken at least 24 grueling months to get to product launch, but the distributor doesn’t have skin in the game and is often fixated on products driving short sales cycles and quick payment.

    When considering a distributor strategy, consider the sales cycle of your product and ensure you identify distributors comfortable working a six- to nine-month process. If your product isn’t ready for commercial release, distributors will focus on products creating a path to commissions.

    At this point, hindsight is 20/20. The distributors have given the ultimate gift of feedback—because in commercial terms, one only gets a couple of bites at the apple to make an impression in the marketplace. It’s hard to make a second impression (and recover with subsequent launches) if the product rollout looks half-baked, with a technology faltering out of the gate. Unfortunately, modifying a design can also mean resubmitting to the FDA.

    As sales falter, inventory grows. This ties up cash. Investing too much in inventory or factory automation before product launch increases company risk, even if it reduces unit cost. Additionally, as sales increase, manufacturing is strained. This problem is solvable—scaling manufacturing should be carefully timed with the product rollout. Manual manufacturing processes can provide flexibility during commercialization, but there should also be a quick and clear path to ramp when needed.

    Once the essentials are covered, the company must consider the estimated usage per institution. This bottom-up approach provides a more accurate sales forecast. When converting an institution, understand the competition and any existing group purchasing organization (GPO) contracts needing circumvention.

    GPOs and integrated delivery networks (IDN, a system of providers) control much of the decision-making for capital equipment. A healthy GPO and IDN strategy must exist. According to Definitive Healthcare, 97 percent of hospitals are affiliated with GPOs. The Healthcare Supply Chain Association also suggests GPOs manage about 72 percent of the purchases in hospitals.

    U.S. health data based on the U.S. Centers for Medicare and Medicaid Services found from 2013 to 2022, GPOs are expected to generate savings of up to $864 billion for the U.S. health system and their members. GPOs like Premier and Vizient together supply close to 1 million hospital beds. Vizient alone represents almost $100 billion in annual purchasing volume, but don’t assume members are loyal to a corporate contract. More than ever, cost containment and patient outcome data is crucial to survival.

    Almost 80 percent of institutional C-Suite executives have resource utilization programs in place to control the use of supplies and services. Value analysis committees delay the introduction of new products because each potential entrant must be vetted. Companies need to articulate the product’s measurable value, then prove it. If not, new devices will be commoditized (resulting in a lower price) or never purchased. They also have to be creative—for example, through an equipment lease, pay-per-use agreement, or risk-based contracts. Companies also need to know which contracting approaches provide institutional customers the most value.

    Obsess over customer feedback during the development phase and embrace negative input. If treated and handled correctly, each negative pearl is worth millions in valuation potential. Throughout the development process, keep an open mind, engage the customer often, and be willing to make changes. Solving a unique clinical problem in close coordination with the customer often results in a disruptive design approach. Hiring the right sales team to sell the right product is the only way to clear some fog on the road ahead. Once this is done, don’t underestimate the value of a comprehensive sales strategy. Commercialization will always be a time of high anxiety, but there’s no quicker road to success than taking the time to do it right. 


    Steve Maylish has been part of the medical device community for more than 30 years. He is currently chief commercial officer for Fusion Biotec, an Irvine, Calif.-based contract engineering firm that brings together art, science, and engineering to create medical devices. Early in his career, Maylish held positions at Fortune 100 corporations such as Johnson & Johnson, Shiley, Sorin Group, Baxter Healthcare, and Edwards Lifesciences.

    Ben Bobo is a senior medical device/healthcare technology executive with experience as a CEO, CCO, and COO. His background includes extensive sales and marketing successes in VC-funded start-up, early commercial stage, and multibillion-dollar corporate environments. Bobo has held positions with Edwards Lifesciences, Cardio Thoracic Systems, Guidant, and CardioVention. He has a BS in economics and an MBA from the University of Phoenix.
    Related Searches
    • standard
    • edwards lifesciences
    • voice
    • medical
    Related Knowledge Center
    • R&D & Design
    Suggested For You
    Medtech Matters: Medtronic Medtech Matters: Medtronic's Robotic Surgery Status
    TPI Partners with Zeiss TPI Partners with Zeiss
    Freudenberg Medical Expands Injection Molding Operations Freudenberg Medical Expands Injection Molding Operations
    CHF Solutions Appoints CEO CHF Solutions Appoints CEO
    Medtech Matters: Surgeons Scrubbing In Virtually Medtech Matters: Surgeons Scrubbing In Virtually
    FineHeart Successfully Tests Wireless TET System FineHeart Successfully Tests Wireless TET System
    CMS Expedites Breakthrough Device Access; Industry Applauds CMS Expedites Breakthrough Device Access; Industry Applauds
    Medtech Matters: Talking Robotic Surgery with Zimmer Biomet Medtech Matters: Talking Robotic Surgery with Zimmer Biomet
    Vonco Products Receives ISO 13485:2016 Certification Vonco Products Receives ISO 13485:2016 Certification
    BioSerenity Achieves FDA Clearance for Wearable Device System BioSerenity Achieves FDA Clearance for Wearable Device System
    Greenlight Guru and Nelson Labs Partner Greenlight Guru and Nelson Labs Partner
    Katena Products Welcomes New CEO Katena Products Welcomes New CEO
    Medtech Veteran Joins VivaLNK Board Medtech Veteran Joins VivaLNK Board
    New Company Formed to Develop Peripheral Venous Disease Treatments New Company Formed to Develop Peripheral Venous Disease Treatments
    New Global Headquarters for Freudenberg Medical New Global Headquarters for Freudenberg Medical

    Related Columns

    • Contract Manufacturing | R&D & Design
      Trends for Medtech Contract R&D and Manufacturing

      Trends for Medtech Contract R&D and Manufacturing

      Over the past 10 years, medtech manufacturers from startups to giants have grown their levels of outsourcing to contract R&D and manufacturing partners.
      Maria Shepherd, President and Founder, Medi-Vantage 09.01.20

    • R&D & Design | Surgical
      Sparking Innovation as We Struggle to Find the New Normal

      Sparking Innovation as We Struggle to Find the New Normal

      The goal is to find the best ideas to support orthopedic patients adjusting to additional pain and immobility while they wait for elective surgeries.
      Dawn A. Lissy, Founder & President, Empirical 06.04.20

    • R&D & Design
      Disposable Design: Consider All Interfaces

      Disposable Design: Consider All Interfaces

      The disposable component is becoming more challenging as products get smaller and more complex.
      Will DeMore, Mechanical Engineer, Key Technologies Inc. 06.04.20


    • R&D & Design
      Why Outsourcing Is in: Piecing Out Projects Makes Sense

      Why Outsourcing Is in: Piecing Out Projects Makes Sense

      Getting outside help is a trend both large and small medical device companies are following as outsourcing engineering services continues to gain traction.
      Dawn A. Lissy, President & Founder, Empirical 04.01.20

    • R&D & Design
      Top 10 Considerations for Medtech Inventors

      Top 10 Considerations for Medtech Inventors

      If you or your employer is interested in protecting an invention, then filing a patent application may be the way to go.
      Ryan Connell and Doug Portnow, Schwegman Lundberg & Woessner 04.01.20

    • R&D & Design
      Supercharge Medical Device Innovation Using Effective User Preference Studies

      Supercharge Medical Device Innovation Using Effective User Preference Studies

      User preference and evaluation studies have been a mainstay design tool for medical device development for decades.
      Philip Remedios, Principal, Director of Design & Development, BlackHägen Design 04.01.20


    • R&D & Design | Testing
      FDA Guidelines for Employing X-ray Inspection in Medical Device Development

      FDA Guidelines for Employing X-ray Inspection in Medical Device Development

      Different materials exhibit different radiopacity as a function of material composition (i.e. atomic weight) and thickness.
      Gil Zweig, President, Glenbrook Technologies 01.29.20

    • Digital Health | R&D & Design
      Speed Up or Risk Stepping Down: The New Reality of the Connected Healthcare Development Cycle

      Speed Up or Risk Stepping Down: The New Reality of the Connected Healthcare Development Cycle

      Digital health and connected devices are an extraordinary new tool for delivering on improving patient outcomes.
      Joe McBeth, VP Global Supply Chain, Jabil Healthcare 01.29.20

    • R&D & Design
      Perfecting Drug Delivery Device Design

      Perfecting Drug Delivery Device Design

      Unlike medical products that just need to work, drug delivery devices must also consider intuitiveness, usability, and how it makes the user feel when operated.
      Bryce G. Rutter, Ph.D., Founder & CEO, Metaphase Design Group Inc. 11.04.19


    • R&D & Design
      Best Practices for Industrial Design in the Medical Device Space

      Best Practices for Industrial Design in the Medical Device Space

      This article will outline unique concerns in the medical space and how proper attention to special design considerations is critical.
      Bartosz Korec, Lead Industrial Designer, BlackHägen Design 10.08.19

    • R&D & Design
      Three Crucial Elements of Conducting International Usability Research

      Three Crucial Elements of Conducting International Usability Research

      It is important to conduct usability research throughout the product development cycle.
      Joe Pratt, CHFP, Lead Human Factors Engineer, BlackHägen Design 09.06.19

    • Materials | Packaging & Sterilization | R&D & Design
      Case in Point: Robust Sintered PTFE Material Helps to Reduce Risk of HAIs

      Case in Point: Robust Sintered PTFE Material Helps to Reduce Risk of HAIs

      ...
      Jack Chan, Global Marketing Director—Medical, Porex 07.30.19


    • R&D & Design
      What Is Human Factors Engineering and Why Is It Important?

      What Is Human Factors Engineering and Why Is It Important?

      ...
      Rich Newman, Usability Engineering Manager, BlackHägen Design 07.30.19

    • R&D & Design
      Designing for a Seamless UX

      Designing for a Seamless UX

      ...
      Dr. Bryce Rutter, Founder and CEO, Metaphase Design Group Inc. 06.13.19

    • R&D & Design
      Taking the Waste Out of Product Development

      Taking the Waste Out of Product Development

      ...
      Ron Estes , VP Operations, Estes Design and Manufacturing 05.01.19


    Trending
    • Telemedicine, Regulatory Changes To Characterize Medtech Industry In 2021
    • Masimo Earns CE Mark For New Fingertip Pulse Oximeter
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • Philips Buys Capsule Technologies In $635M Deal
    • Understanding Food-Grade Vs. Biocompatibility For Medical Device Materials
    Breaking News
    • Cretex Companies CEO Steps Down
    • Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    • Endoscopic Hemostasis Devices Market Valued at $730 Million
    • Henry Schein Buys Majority Interest in Prism Medical Products
    • Boston Scientific's Vercise Genus DBS Earns FDA Approval
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Pharmaceutical Focus: A Look at Combination Products
    • The Printed World: Additive Manufacturing in Medtech
    • The Lost Year: 2020 Year in Review
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login